Shanghai Synergy Pharmaceutical Sciences Co. Ltd. and Zhejiang Huahai Pharmaceutical Group Co. Ltd. have patented C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of cancer, autoimmune diseases and inflammatory disorders.
A team from Nanjing Leads Biolabs Co. Ltd. presented the discovery and preclinical characterization of LBL-042, a novel bispecific antibody designed to simultaneously target PD-1 and LILRB1/2, with the aim of improving immune evasion of tumor microenvironment and potentially overcoming resistance to immuno-oncology therapy.
Changchun Genescience Pharmaceuticals Co. Ltd. has reported GSC-000829, a novel and selective FGFR2/FGFR3 inhibitor being developed for the potential treatment of cancer.
DAN-222 is a polymeric nanoparticle covalently conjugated with the topoisomerase I inhibitor camptothecin, which has previously demonstrated promising clinical activity in heavily pretreated patients with breast cancer (NCT05261269).
Recurrence rates and acquired treatment resistance in colorectal cancer have been linked to colorectal cancer stem cells, which are a subpopulation of slowly dividing cells within the tumor environment.
Arkuda Therapeutics Inc. has patented new fused tricyclic mucolipin-1 (MCOLN1; TRPML1) blockers reported to be useful for the treatment of cancer, liver diseases, amyotrophic lateral sclerosis, cardiovascular disorders, frontotemporal dementia, Alzheimer’s, Huntington’s and Parkinson’s disease.
Hangzhou Synrx Therapeutics Biomedical Technology Co. Ltd. recently presented the development and characterization of a novel PARG inhibitor, SYN-608, for the potential treatment of tumors with/without homologous recombination deficiency (HRD).
Tumor cell survival is dependent on phosphate homeostasis, which requires high amounts of energy. Researchers have demonstrated that the silencing of xenotropic and polytropic retrovirus receptor 1 (XPR1) led to reduced tumor growth in an ovarian cancer cell line xenograft, and similar vulnerability was found in lung cancer.
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, with a 5-year survival rate of 18%. Glypican-3 (GPC3) is a protein with high expression in HCC but not in healthy tissue, making it an interesting target for therapy.
RSS
